GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Amarin Corporation plc
Amarin is a biopharmaceutical company whose fate is closely tied to its sole drug, Vascepa, which reduces cardiovascular risks. Its price chart is a dramatic story of rise due to successful clinical trials and subsequent decline due to patent losses and the emergence of generics.
Share prices of companies in the market segment - Heart
Amarin (AMRN) is a pharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based therapies for improving cardiovascular health, with its flagship product, Vascepa. We classify it as a Cardiology company. The chart below shows the dynamics of the cardiac drug sector.
Broad Market Index - GURU.Markets
Amarin is an Irish pharmaceutical company known for its drug Vascepa, which is used to reduce cardiovascular risks. As a component of the GURU.Markets index, it represents the cardiology sector. The chart below represents the entire market. See how Amarin shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AMRN - Daily change in the company's share price Amarin Corporation plc
The daily price change of Amarin, the maker of Vascepa, reflects the risks facing the pharmaceutical industry. Change_co measures volatility associated with patent disputes, sales data, and regulatory decisions. This metric is an important component of complex formulas on System.GURU.Markets that analyze companies with a single key product.
Daily change in the price of a set of shares in a market segment - Heart
Amarin Corporation plc is a pharmaceutical company. This chart highlights the high volatility of the sector. Comparing it to AMRN, whose success depends on a single drug, helps to understand its high concentration risks and generic competition.
Daily change in the price of a broad market stock, index - GURU.Markets
Amarin is a biopharmaceutical company known for its fish oil-based drug for reducing cardiovascular risk. Its history exemplifies the extreme volatility and patent risks of biotech. The chart below illustrates general market fluctuations, making Amarin's trajectory particularly instructive.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Amarin Corporation plc
For Amarin Corporation, the year-over-year trend is a story of survival following the loss of patent protection for its blockbuster drug Vascepa. Its market capitalization over the past 12 months reflects a sharp decline in revenue due to the emergence of generics and the company's attempts to find new markets and strategies for its fish oil-based drug.
Annual dynamics of market capitalization of the market segment - Heart
Amarin Corporation plc is a biopharmaceutical company whose success was built on the cardiovascular risk-reduction drug Vascepa. This chart shows how generic competition and its efforts to protect its intellectual property impact its complex dynamics.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amarin, with its drug Vascepa, is a story of a single product. Its stock price reflects not economic cycles, but rather the drug's sales volume and the threat of generics. The chart is a classic example of a biotech company, where the fate of an entire company hinges on a single patent.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Amarin Corporation plc
Amarin, a pharmaceutical company, is valued at a single product. The monthly fluctuations in the chart reflect sales data for its drug Vascepa and, more importantly, the impact of generic competition, which is putting significant pressure on its revenue.
Monthly dynamics of market capitalization of the market segment - Heart
Amarin Corporation is a pharmaceutical company whose main product is Vascepa, a fish oil-based drug for reducing cardiovascular risk. The company's future depends on Vascepa sales volumes and generic competition. The chart of the cardiology pharmaceutical market segment reveals general trends that can be used to assess the market challenges facing Amarin.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amarin Corporation, whose fate is closely tied to sales of its key drug, Vascepa, operates in the pharmaceutical world. The company's stock performance is determined by sales data, regulatory decisions, and patent disputes, rather than general economic cycles, creating a unique market profile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Amarin Corporation plc
Amarin, a biopharmaceutical company whose flagship product is a fish oil-based drug for reducing cardiovascular risk, faces competition from generics. Its weekly stock price reflects sales volumes, patent litigation, and its efforts to enter new markets.
Weekly dynamics of market capitalization of the market segment - Heart
Single-product biopharmaceutical companies like Amarin face a common risk of losing patent protection. The chart below illustrates how the market evaluates such situations. It compares how well Amarin is coping with generic competition compared to other companies in a similar position.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Amarin is a pharmaceutical company whose main product, Vascepa, is a fish oil-based drug used to reduce cardiovascular risk. Its stock is highly dependent on patent disputes and sales volumes. The chart below shows how much of its performance is driven by these unique factors, rather than the market.
Market capitalization of the company, segment and market as a whole
AMRN - Market capitalization of the company Amarin Corporation plc
Amarin Corporation's market capitalization chart is a dramatic story of the rise and fall of a single product. Its precipitous decline from its peak reflects the loss of patent protection for its drug Vascepa. Its current value reflects investors' assessment of its efforts to maintain market share in the US and expand sales in Europe, as well as its remaining cash.
AMRN - Share of the company's market capitalization Amarin Corporation plc within the market segment - Heart
Amarin Corporation is a pharmaceutical company whose main product, Vascepa, is used to reduce cardiovascular risks. In the cardiac drug segment, its market capitalization reflects the commercial success of this drug. Fluctuations in this metric are closely linked to patent disputes and generic competition, which are key risks for the company.
Market capitalization of the market segment - Heart
Below is a chart showing the total value of the entire pharmaceutical sector focused on cardiovascular disease treatment. For Amarin, whose key product, Vascepa, this line maps the battle against generics. Its dynamics reflect the market's assessment of the company's ability to defend its blockbuster from patent challenges and competition.
Market capitalization of all companies included in a broad market index - GURU.Markets
Amarin Corporation produces a fish oil-based drug for reducing cardiovascular risk. Its market capitalization is an assessment of its market prospects and the competition from generics. It reflects how the market values a drug with a unique yet challenging position.
Book value capitalization of the company, segment and market as a whole
AMRN - Book value capitalization of the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose main product is the fish oil-based drug Vascepa. Its book value is its financial resources and finished product inventory. This capital is used for marketing and further research. How has it changed since the patent was lost? The chart below tells the story.
AMRN - Share of the company's book capitalization Amarin Corporation plc within the market segment - Heart
Amarin Corporation plc is a pharmaceutical company whose success is built on a single drug, Vascepa. Its balance sheet reflects the value of the manufacturing and logistics infrastructure required for the global production and supply of this drug. The chart shows its share of the tangible assets supporting this specific product.
Market segment balance sheet capitalization - Heart
Amarin, a biopharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D, commercial infrastructure, and control over the production of its drug, Vascepa. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Amarin's assets include its intellectual property for Vascepa, as well as its manufacturing and commercial capabilities for its global distribution. Its book value reflects the capital invested in clinical research and marketing of this unique heart drug. The chart below illustrates the scale of this business.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Amarin Corporation plc
Amarin's balance sheet is its intellectual property for Vascepa. The sharp decline in its market value below book value is a consequence of losing patent disputes, which paved the way for cheaper generics. The chart illustrates how the loss of patent protection destroys intangible value.
Market to book capitalization ratio in a market segment - Heart
Amarin is a pharmaceutical company whose main product is the fish oil-based drug Vascepa. Its valuation on this chart is heavily dependent on the sales volume of this drug and generic competition, which creates constant pressure on its business.
Market to book capitalization ratio for the market as a whole
Amarin Corporation is a pharmaceutical company known for its fish oil-based drug Vascepa. Its market valuation is heavily dependent on patent protection, sales volume, and new research results. This chart shows how these factors influence the market-to-book value ratio.
Debts of the company, segment and market as a whole
AMRN - Company debts Amarin Corporation plc
Amarin Corporation, a pharmaceutical company whose fortunes are closely tied to its cardiovascular risk-reducing drug, uses capital for marketing and further research. The company's debt policy reflects its struggle with generics. This chart shows how the company manages its finances under intense competitive pressure.
Market segment debts - Heart
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. After losing its patent protection, the company faced competition from generics. This chart shows how Amarin manages its finances and debt in the face of rapidly changing market conditions.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose success depends largely on a single cardiovascular drug. This chart shows its financial structure. Debt in this situation can be particularly risky, as any sales or patent issues with its key product directly impact its ability to service the debt.
Market segment debt to market segment book capitalization - Heart
Amarin Corporation produces Vascepa, a fish oil-based drug used to reduce cardiovascular risk. The company faces competition from generics. The chart shows the overall debt burden in the pharmaceutical industry, which helps assess how Amarin finances its marketing efforts and research into new indications for its drug.
Debt to book value of all companies in the market
Amarin Corporation, a pharmaceutical company focused on cardiovascular diseases, invests heavily in clinical research and marketing. This chart, showing the market's total debt load, allows one to assess how the company manages its balance sheet after launching a key product and in the face of patent competition.
P/E of the company, segment and market as a whole
P/E - Amarin Corporation plc
Amarin Corporation is a pharmaceutical company focused on treating cardiovascular diseases. Its key product is Vascepa, a fish oil-based medication. This chart shows how the market is assessing its competition against generics. The dynamics reflect the impact of competition on sales and the company's efforts to protect its intellectual property.
P/E of the market segment - Heart
Amarin is a pharmaceutical company whose fate hinges on a single drug. This chart shows the average valuation for the pharmaceutical sector. It helps understand the discount the market is placing on Amarin due to the threat of generics and its lack of diversification compared to other pharmaceutical companies.
P/E of the market as a whole
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing drugs to improve cardiovascular health. Its flagship product is Vascepa. This chart reflects overall sentiment in the pharmaceutical sector. It helps understand what influences AMRN's valuation more: general market trends or specific factors such as patent disputes and competition.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose primary product is designed to reduce cardiovascular risk. Its future profitability depends on sales volumes of this drug and competition from generics. This chart reflects analyst expectations regarding the company's revenue stability and future market prospects.
%20P%2FE%20Amarin%20Corporation%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Amarin-Corporation-plc&v=1772513772490 "Chart of the company's future (projected) P/E Amarin Corporation plc")
Future (projected) P/E of the market segment - Heart
Amarin Corporation is a pharmaceutical company whose primary product is Vascepa, used to reduce cardiovascular risks in certain patient groups. This graph reflects expectations for its future profitability, which is heavily dependent on its ability to protect its intellectual property and compete with generics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772513772574 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Amarin Corporation focuses on treating cardiovascular diseases, and its key product is a fish oil-based drug. This general expectations chart provides a backdrop against which investors can assess the risks associated with patent protection and competition, which are crucial for pharmaceutical companies with a single product.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513772595 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose main product is designed to reduce cardiovascular risks. This chart reflects its struggle with generic competition after losing patent protection. Financial results demonstrate how successfully the company is maintaining sales of its brand-name drug.
Profit of companies in the market segment - Heart
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. Its profitability is closely tied to sales of this drug and generic competition. The company's history exemplifies how patent protection and market exclusivity influence financial performance in the pharmaceutical industry.
Overall market profit
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. Its success depends on prescription volumes and competition. The overall economic situation, reflected in this chart, does not directly affect demand, but it does impact the solvency of healthcare systems and patients.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose main product, Vascepa, is used to reduce cardiovascular risk. This chart reflects analysts' expectations for future earnings, which are heavily dependent on generic competition and the company's success in expanding sales in international markets, such as Europe.
%20profit%20of%20the%20company%20Amarin%20Corporation%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Amarin-Corporation-plc&v=1772513772657 "Graph of future (projected) profit of the company Amarin Corporation plc")
Future (predicted) profit of companies in the market segment - Heart
Amarin Corporation is a pharmaceutical company whose primary product is designed to reduce cardiovascular risk in patients with high triglyceride levels. The sector profitability projections shown in the graph reflect the vast cardiovascular market. This chart helps assess how Amarin fares against generic competition.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772513772673 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Amarin Corporation is a pharmaceutical company known for its fish oil-based drug Vascepa, which reduces cardiovascular risk. Sales volumes depend on physician prescriptions and insurance coverage. The overall health of the economy, reflected in the graph, affects healthcare budgets and patient access to medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513772679 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose flagship product, Vascepa, is designed to reduce cardiovascular risks. This chart shows how the market values the company's revenue after the loss of patent exclusivity and the introduction of generic versions. This trend reflects its ability to compete and expand sales in international markets.
P/S market segment - Heart
Amarin Corporation is a pharmaceutical company focused on developing drugs to improve cardiovascular health. Its key product is Vascepa. This chart shows the average revenue estimate in the pharmaceutical industry. It helps assess how investors perceive the company after losing patent protection and facing generic competition.
P/S of the market as a whole
Amarin Corporation is a pharmaceutical company whose main product, Vascepa, is a fish oil-based drug used to reduce cardiovascular risk in certain patient groups. This chart helps understand how investors evaluate the company's revenue, which depends on sales of a single key drug, in the face of competition and patent disputes.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose main product, Vascepa, is used to reduce cardiovascular risk. This chart shows how investors estimate its future earnings. The valuation is heavily dependent on Vascepa's sales volume, generic competition, and success in international markets.
%20P%2FS%20Amarin%20Corporation%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Amarin-Corporation-plc&v=1772513772770 "The graph of the company's future (projected) P/S Amarin Corporation plc")
Future (projected) P/S of the market segment - Heart
Amarin Corporation is a pharmaceutical company focused on developing drugs to improve cardiovascular health. This chart compares market expectations for its future revenue with other cardiology companies. The estimate reflects investor opinions on the sales of its key drug, Vascepa, and the challenges associated with patent protection.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772513772817 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. Its future depends on patent protection and competition. This overall revenue expectation schedule is less important for Amarin than the decisions of the courts and regulators that determine its market share and pricing.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513772845 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Amarin Corporation plc
This chart shows the revenue of Amarin Corporation, a pharmaceutical company whose main product is Vascepa, a drug used to reduce cardiovascular risks. Revenue trends in recent years have been heavily influenced by generic competition following the loss of patent protection in the US. This is a classic example of how a "patent cliff" can dramatically alter a pharmaceutical company's revenue trajectory.
Sales of companies in the market segment - Heart
Amarin Corporation is a pharmaceutical company whose flagship product, Vascepa, is a highly purified omega-3 fatty acid-based drug for reducing cardiovascular risk. This chart shows revenue in the cardiac pharmaceutical sector. It reflects the vast cardiovascular prevention market and Amarin's struggle to maintain market share following the introduction of generics.
Overall market sales
Amarin Corporation is a pharmaceutical company whose flagship product, Vascepa, is used to reduce cardiovascular risks. Demand for the drug depends on its clinical effectiveness and acceptance by physicians. Economic cycles, as reflected in this chart, have little impact on demand for life-saving cardiac medications, but they do impact the solvency of healthcare systems.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose flagship product, Vascepa, is designed to reduce cardiovascular risk. This revenue projection chart is under close scrutiny. Its dynamics reflect analysts' expectations for Vascepa sales volumes in the face of generic competition and the company's efforts to protect its intellectual property.
%20sales%20of%20the%20company%20Amarin%20Corporation%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Amarin-Corporation-plc&v=1772513773059 "Schedule of future (projected) sales of the company Amarin Corporation plc")
Future (projected) sales of companies in the market segment - Heart
Amarin Corporation is a pharmaceutical company focused on developing drugs to improve cardiovascular health. Its flagship product, Vascepa, is used to lower triglyceride levels. This chart shows projected revenue for the entire cardiac drug sector, reflecting the vast market and need for cardiovascular treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772513773082 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Amarin Corporation is a pharmaceutical company focused on the treatment of cardiovascular diseases. Demand for its flagship drug, Vascepa, is driven by medical needs. However, the overall economic situation impacts healthcare budgets and patients' ability to afford treatment, which indirectly affects sales.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513773134 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose fate is closely tied to a single product—the heart drug Vascepa. This chart clearly demonstrates how the company's profitability, previously protected by patents, plummeted after the introduction of generics, a classic risk for a single-product pharmaceutical company.
Market segment marginality - Heart
Amarin Corporation is a pharmaceutical company focused on the development and commercialization of cardiovascular health treatments, best known for its drug Vascepa. This chart shows the company's profitability. Its profitability is directly dependent on Vascepa sales volumes and its ability to protect its intellectual property from generics.
Market marginality as a whole
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. Its success depends less on the general economic cycles shown in this chart and more on regulatory decisions, patent protection, and generic competition, which directly impact sales.
Employees in the company, segment and market as a whole
Number of employees in the company Amarin Corporation plc
Amarin Corporation is a pharmaceutical company whose main product is a fish oil-based drug for reducing cardiovascular risk. This chart shows the team facing the loss of patent protection. The staffing trend likely reflects the sharp reduction in the commercial team following the introduction of generic versions.
Share of the company's employees Amarin Corporation plc within the market segment - Heart
Amarin is a pharmaceutical company whose success depends largely on a single drug, Vascepa. Its promotion and sales require a large and effective team of sales representatives. This chart directly reflects its sales efforts, showing the proportion of pharmaceutical salespeople it employs to maximize the market share of its key product.
Number of employees in the market segment - Heart
Amarin Corporation is a pharmaceutical company whose flagship product, Vascepa, is used to reduce cardiovascular risks. This graph illustrates the life cycle of a single pharmaceutical product. Employment dynamics, particularly in the sales department, fluctuated dramatically depending on patent disputes and regulatory decisions, highlighting the risks associated with dependence on a single drug.
Number of employees in the market as a whole
Amarin Corporation is a pharmaceutical company known for its fish oil-based drug for reducing cardiovascular risk. Its workforce dynamics, particularly sales, are highly dependent on patent protection and competition. This graph illustrates how the life cycle of one key product influences the fate of the entire company, which contrasts with a diversified economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Amarin Corporation plc (AMRN)
Amarin Corporation is a pharmaceutical company whose main product, Vascepa (based on fish oil), is used to reduce cardiovascular risks. This chart shows the market value of a company dependent on a single product. This value can fluctuate significantly based on patent news, clinical data, and generic competition.
%20of%20the%20company%20Amarin%20Corporation%20plc%20(AMRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Amarin-Corporation-plc-AMRN&v=1772513773423 "Chart of market capitalization per employee (in thousands of dollars) of the company Amarin Corporation plc (AMRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Amarin Corporation is a pharmaceutical company known for its fish oil-based drug for reducing cardiovascular risk. This metric helps assess the market's appreciation of their core product and the potential for future developments. Deviation from the industry average may indicate the uniqueness of their market niche and the effectiveness of their commercial strategy.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772513773478 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Amarin Corporation is a pharmaceutical company whose primary product is designed to reduce cardiovascular risks. This metric reflects a business built around a single drug. Market capitalization is highly dependent on sales volume, patent protection, and competition. This demonstrates both the potential and the risks of such a focused model.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513773500 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Amarin Corporation plc (AMRN)
Amarin Corporation is a pharmaceutical company whose main product is Vascepa, a fish oil-based medication for reducing cardiovascular risk. Their business was built on a single drug. This chart shows the profitability of this single product. Fluctuations in this indicator are highly dependent on generic competition and the effectiveness of their sales team.
%20Chart%20Amarin%20Corporation%20plc%20(AMRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Amarin-Corporation-plc-AMRN&v=1772513773535 "Company Profit Per Employee (in thousands of dollars) Chart Amarin Corporation plc (AMRN)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Amarin is a pharmaceutical company whose revenue is almost entirely dependent on a single product: Vascepa, a fish oil-based medication. This metric demonstrates how effectively their (recently downsized) sales team and corporate staff can maximize profits from this single, albeit widely known, asset.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772513773591 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Amarin Corporation is a pharmaceutical company whose fortunes depend almost entirely on a single product—Vascepa, a cardiovascular risk-reducing drug. This chart shows how effectively their sales team (sales and marketing) maximizes sales of this single drug, covering all of the company's R&D and administrative costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513773642 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Amarin Corporation plc (AMRN)
Amarin Corporation is a pharmaceutical company known for its fish oil-based drug Vascepa, which reduces cardiovascular risk. This graph shows the life cycle of a single product. The revenue per employee trend reflects sales volume, generic competition, and efforts to enter new markets.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Amarin-Corporation-plc-AMRN&v=1772513773661 "Sales chart per company employee Amarin Corporation plc (AMRN)")
Sales per employee in the market segment - Heart
Amarin (AMRN) is a pharmaceutical company whose flagship product is Vascepa, a fish oil-based drug approved for reducing cardiovascular risk. This chart shows how much revenue each employee (primarily the sales team) generates from Vascepa sales. This is an indicator of their commercial performance, especially in the face of the emergence of generic versions.
Sales per employee for the market as a whole
Amarin Corporation is a pharmaceutical company whose main product is Vascepa/Vazkepa, a fish oil-based drug for reducing cardiovascular risk. This metric is critical for them, especially after losing patent protection in the US. It demonstrates how effectively their (reduced) sales team generates revenue in the face of generic competition.
Short shares by company, segment and market as a whole
Shares shorted by company Amarin Corporation plc (AMRN)
Amarin is a pharmaceutical company whose fate was tied to a single drug, Vascepa. This chart reflects bearish sentiment. The bears won: after the company lost the patent lawsuits, cheap generic versions entered the market, leading to a collapse in revenue and a plunge in Amarin's stock.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Amarin-Corporation-plc-AMRN&v=1772513773720 "Short Shares Chart for the Company Amarin Corporation plc (AMRN)")
Shares shorted by market segment - Heart
Amarin is the pharmaceutical company behind Vascepa (a drug used to reduce cardiovascular risk). This chart shows bearish bets. "Shorts" here are bets on its "death." After Vascepa lost its patent protection, investors are betting the company won't survive due to generic competition.
Shares shorted by the overall market
Amarin Corporation is a pharmaceutical company whose main product (Vascepa) is used to reduce cardiovascular risks. This drug is dependent on patents and competition. This chart reflects the general level of fear. When the market is in panic, investors may overestimate the risks associated with generic competition, which increases pressure on the stock.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Amarin Corporation plc (AMRN)
Amarin (AMRN) is a pharmaceutical company whose only product is Vascepa, a fish oil (omega-3) drug for reducing cardiovascular risk. Their business has been hit hard by the loss of patent protection. This chart measures sentiment. It shows "oversold" (below 30) amid a sharp decline in sales due to generics, or "overbought" (above 70) due to rumors.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Amarin-Corporation-plc-AMRN&v=1772513773789 "RSI 14 indicator chart for the company's stock Amarin Corporation plc (AMRN)")
RSI 14 Market Segment - Heart
Amarin (AMRN) is essentially a "single-product company." Their fortunes revolve around Vascepa, a fish oil (omega-3) drug for reducing cardiovascular risk. The RSI_14_Seg for "Heart" (biotech) shows the overall sentiment. The chart helps us understand: is AMRN's decline a patent bust, or is the entire sector oversold?
RSI 14 for the overall market
Amarin (AMRN), a pharmaceutical company, sees investor sentiment, not demand, in this chart. Demand for its heart medications is stable. However, in times of panic, investors may fear "single-product risk" and generic competition, which puts pressure on AMRN shares despite its stable underlying business.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AMRN (Amarin Corporation plc)
Amarin Corporation is a biopharmaceutical company whose sole key product is Vascepa/Vazkepa. It is a fish oil-based drug approved for reducing cardiovascular risk in patients with high triglyceride levels. This chart shows the average analyst forecast, which is heavily dependent on Vascepa's competition from generics in the US and sales growth in Europe.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AMRN-Amarin-Corporation-plc&v=1772513773871 "A chart showing analyst consensus forecasts for the expected stock price. AMRN (Amarin Corporation plc)")
The difference between the consensus estimate and the actual stock price AMRN (Amarin Corporation plc)
Amarin is a biopharmaceutical company whose success is built on Vascepa, a drug used to reduce cardiovascular risks. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current share price and the consensus target price, indicating whether experts believe in its European expansion amid the US patent wars.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AMRN-Amarin-Corporation-plc&v=1772513773886 "A chart showing the difference between the consensus forecast and the actual stock price. AMRN (Amarin Corporation plc)")
Analyst consensus forecast for stock prices by market segment - Heart
Amarin is essentially a one-product company, Vascepa, a fish oil-based drug for reducing cardiovascular risk. Its fate hinges on the battle with generics. This chart shows analysts' overall expectations for the entire cardiology sector. It reflects whether experts believe the market as a whole can grow, despite price wars.
Analysts' consensus forecast for the overall market share price
Amarin Corporation is a biopharmaceutical company whose flagship drug, Vascepa, is designed to reduce cardiovascular risks. This sector is often considered defensive. This chart shows the overall market sentiment among experts. For Amarin, it serves as a backdrop: during periods of pessimism, investors may value the stability of the pharmaceutical industry, but the company's fate depends more on generic competition.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Amarin Corporation plc
Amarin is a pharmaceutical company whose fate depends almost entirely on a single product: Vascepa, a drug designed to reduce cardiovascular risks. This chart is a comprehensive barometer of this single-bet. Its dynamics reflect not a diversified portfolio, but Vascepa's fierce battle with generics and the company's efforts to defend its share of this vast market.
AKIMA Market Segment Index - Heart
Amarin is a pharmaceutical company whose business is built on a single drug, Vascepa, designed to reduce cardiovascular risks. This comprehensive index evaluates companies based on R&D and commercial success. The chart shows the average value across the entire pharmaceutical segment. This benchmark is critical: it helps understand how Amarin, with its reliance on a single product and the battle against generics, compares favorably to the average competitor.
The AKIM Index for the overall market
Amarin is a biopharmaceutical company whose flagship product, Vascepa, aims to reduce cardiovascular risks. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this mature commercial company, facing generic competition, stacks up against overall economic trends and sentiment in the healthcare sector.
